NALMEFENE HCL Trademark

Trademark Overview


On Thursday, March 10, 2022, a trademark application was filed for NALMEFENE HCL with the United States Patent and Trademark Office. The USPTO has given the NALMEFENE HCL trademark a serial number of 97306650. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Thursday, September 12, 2024. This trademark is owned by Purdue Pharma L.P.. The NALMEFENE HCL trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Pharmaceuticals, namely, opioid antagonists; Syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Syringes filled with opioid antagonists; Injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectors filled with opioid antagonists; Injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectable pharmaceuticals, namely, opioid antagonists
nalmefene hcl

General Information


Serial Number97306650
Word MarkNALMEFENE HCL
Filing DateThursday, March 10, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateThursday, September 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, January 17, 2023

Trademark Statements


Description of MarkThe mark consists of the words Nalmefene HCl beneath 5 small squares and three horizontal lines that transition from solid to decreasing shading.
Goods and ServicesPharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Pharmaceuticals, namely, opioid antagonists; Syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Syringes filled with opioid antagonists; Injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectors filled with opioid antagonists; Injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectable pharmaceuticals, namely, opioid antagonists
NOT AVAILABLE"NALMEFENE HCL"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 16, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePurdue Pharma L.P.
Party Type20 - Owner at Publication
Legal Entity Type13 - Limited Partnership
AddressStamford, CT 06901

Party NamePurdue Pharma L.P.
Party Type10 - Original Applicant
Legal Entity Type13 - Limited Partnership
AddressStamford, CT 06901

Trademark Events


Event DateEvent Description
Tuesday, June 14, 2022PRIORITY ACTION WRITTEN
Monday, March 14, 2022NEW APPLICATION ENTERED
Wednesday, March 16, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 17, 2022NOTICE OF DESIGN SEARCH CODE E-MAILED
Tuesday, June 7, 2022ASSIGNED TO EXAMINER
Tuesday, June 14, 2022PRIORITY ACTION E-MAILED
Tuesday, June 14, 2022NOTIFICATION OF PRIORITY ACTION E-MAILED
Friday, December 9, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, December 9, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, December 10, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 15, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 17, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 17, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, December 28, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, September 8, 2023SOU EXTENSION 1 GRANTED
Tuesday, March 14, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, September 8, 2023SOU TEAS EXTENSION RECEIVED
Friday, September 8, 2023SOU EXTENSION 1 FILED
Tuesday, September 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 12, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, March 12, 2024SOU EXTENSION 2 GRANTED
Tuesday, March 12, 2024SOU EXTENSION 2 FILED
Wednesday, March 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 12, 2024SOU TEAS EXTENSION RECEIVED
Thursday, September 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 12, 2024SOU EXTENSION 3 FILED
Thursday, September 12, 2024SOU EXTENSION 3 GRANTED